ChemicalBook > Product Catalog >API >Blood System Drugs >Anticoagulant and Antiplatelet Drugs >Anagrelide

Anagrelide

Anagrelide Suppliers list
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: +8618523575427
Email: sales@conier.com
Products Intro: Product Name:anagrelide
CAS:68475-42-3
Purity:0.99 Package:1kg,25kg
Company Name: career henan chemical co
Tel: +86-0371-86658258 15093356674;
Email: factory@coreychem.com
Products Intro: Product Name:Anagrelide
CAS:68475-42-3
Purity:99% Package:1KG;7USD
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354 +1-00000000000
Email: marketing@targetmol.com
Products Intro: Product Name:Anagrelide;Anagrelidum;Anagrelida;Xagrid
CAS:68475-42-3
Purity:100.00% Package:1 mL * 10mM (in DMSO);10 mg;100 mg;25 mg;5 mg;50 mg Remarks:REAGENT;FOR LABORATORY USE ONLY
Company Name: Dideu Industries Group Limited
Tel: +86-29-89586680 +86-15129568250
Email: 1026@dideu.com
Products Intro: Product Name:Anagrelide
CAS:68475-42-3
Purity:99.9% Package:1g;1.1USD Remarks:FDA GMP CEP Approved Manufacturer
Company Name: AFINE CHEMICALS LIMITED
Tel: 0571-85134551
Email: info@afinechem.com
Products Intro: Product Name:ANAGRELIDE
CAS:68475-42-3
Purity:98%+ Package:Standard or custom package Remarks:excellent quality and reliable supplier

Anagrelide manufacturers

  • Anagrelide
  • Anagrelide pictures
  • $50.00 / 1kg
  • 2023-04-20
  • CAS:68475-42-3
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 50 tons
  • Anagrelide USP/EP/BP
  • Anagrelide USP/EP/BP pictures
  • $1.10 / 1g
  • 2021-08-05
  • CAS:68475-42-3
  • Min. Order: 1g
  • Purity: 99.9%
  • Supply Ability: 100 Tons min
  • Anagrelide
  • Anagrelide pictures
  • $7.00 / 1KG
  • 2019-12-31
  • CAS:68475-42-3
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 100KG
Anagrelide Basic information
Product Name:Anagrelide
Synonyms:ANAGRELIDE;6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)one;6,7-Dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one;Anagrelidebase;6,7-dichloro-1,5-dihydroiMidazo 2,1-b quinaz...;IMidazo[2,1-β]quinazolin-2(3H)-one,6,7-dichloro-1,5-dihydro-;6,7-Dichloro-5,10-dihydroimidazo[2,1-b]quinazolin-2(3H)-one;Anagrelide analogue: 6-chloro-1,2,3,5-tetrahydro iMidazo [2,1-b]quinazolin-2-one
CAS:68475-42-3
MF:C10H7Cl2N3O
MW:256.09
EINECS:1312995-182-4
Product Categories:Pharmaceutical intermediate
Mol File:68475-42-3.mol
Anagrelide Structure
Anagrelide Chemical Properties
Melting point 280 °C
density 1.77±0.1 g/cm3(Predicted)
storage temp. 2-8°C
pkapKa 2.87 (H2O t=25 I=0.025) (Uncertain);10(H2O t=25 I=0.025) (Uncertain)
Water Solubility slightly soluble
CAS DataBase Reference68475-42-3(CAS DataBase Reference)
Safety Information
Hazardous Substances Data68475-42-3(Hazardous Substances Data)
MSDS Information
Anagrelide Usage And Synthesis
OriginatorAgrylin,Shire Pharmaceuticals
Usesthe treatment of primary thrombocytosis
UsesAnagrelide; Potent PDE 3 inhibitorIt can be used to inhibit cancer cell invasion.
DefinitionChEBI: A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.
Manufacturing Process6,7-Dicloro-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one was produced from 6-chloro-7-bromo-1,2,3,5-tetrahydroimidazo[2,1-b]quinozolin-2-one by substitution the bromine an equimolar quantity chlorine.
6-Chloro-7-bromo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one was produced next way: to a solution of 1.30 g (8 mmole) of anhydrous ferric chloride in 30 ml of nitromethane was added 1.30 g (5 mmole) of solid 6- chloro-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one and 0.80 g (5 mmole) of bromine. The system was stoppered, warmed to 50°C in an oil bath overnight, cooled to room temperature and the solvent removed in vacuo. The resulting solid was suspended in water (50 ml), the mixture was made basic (pH=10) with sodium bicarbonate and stirred at home temperature for 20 min. The solid was filtered under suction, washed with water, then isopropyl alcohol and dried yielding 1.19 g of 6-chloro-7-bromo- 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (78% yield). Purification was effected by formation of the hydrochloride salt (mp 275°C) from acetonitrile.
6-Chloro-1,2,3,5,-tetrahydroimidazo[2,1-b]quinazolin-2-one was produced from 6-chloro-2-nitrobenzylchloride, ethylglycine hydrochloride and cyanogen bromide in 3 steps.
Brand nameAgrylin (Shire).
Therapeutic FunctionPlatelet aggregation inhibitor
Clinical UsePlatelet-reducing agent
Enzyme inhibitorThis potent platelet aggregation inhibitor (FW = 256.09 g/mol; CAS 68475-42-3), also known as 6,7-dichloro-1,5-dihydroimidazo[2,1- b]quinazolin-2(3H)-one, BL-4162A, and Agrylin?, blocks the action of a variety of aggregating agents added platelet rich plasma, EC50 < 1 μg/mL, or 4 nM. Primary Mode of Action: Although the exact mechanism of its selective inhibition of megakaryocyte (MK) production of platelets remains uncertain, anagrelide is known to be a potent inhibitor of phosphodiesterase-II (IC50 = 36 nM) and lipoprotein-associated phospholipase A2 (or Lp-PLA2), the latter also known as platelet-activating factor acetylhydrolase (or PAF-AH). PDE-II hydrolyzes both cGMP and cAMP. Binding of cGMP to its regulatory GAF-B domain favors cAMP hydrolysis to 5’-AMP, thereby reducing cGMP hydrolysis to 5’-GMP. This property, which facilitates cross-regulation of the cAMP and cGMP pathways, suggests that a potent PDE-II inhibitor should potentiate the effects of cAMP and/or cGMP, the concentrations of which should increase in anagrelide-sensitive cells. Lp-PLA2 plays pivotal role in platelet maturation by specifically hydrolyzing Platelet-Activating Factor (PAF = acetyl-glyceryl-ether-phosphorylcholine) as well as other glycerophos-pholipids containing short, truncated, and/or oxidized fatty acyl groups at the sn-2 position of the glycerol backbone. At a final concentration of 100 ng/mL, anagrelide selectively blocks in vitro MK maturation, resulting in a 50% decrease in the total number of CD41a+ MKs. In humans, anagreline has the intriguing ability to promote as a species-specific platelet-lowering activity at dose levels lower than those required to inhibit platelet aggregation. Target(s): collagen- and immune complexinduced platelet aggregation and release; suppresses megakaryocytopoiesis by reducing the expression levels of the transcription GATA-1 and FOG-1 via a PDEIII-independent mechanism that is differentiation context-specific but does not involve inhibition of MPL-mediated early signal transduction events.
Drug interactionsPotentially hazardous interactions with other drugs
Aspirin: potential risks and benefits must first be assessed, additive antiplatelet effect.
Cilostazol: avoid concomitant use.
Grapefruit juice: may reduce clearance of anagrelide.
Phosphodiesterase inhibitors: avoid with milrinone and enoximone.
MetabolismAnagrelide is primarily metabolised by CYP1A2; less than 1% is recovered in the urine as anagrelide. Two major urinary metabolites, 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline and 3-hydroxy anagrelide (pharmacologically active) have been identified. The mean recovery of 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline in urine is approximately 18-35% of the administered dose.
Tag:Anagrelide(68475-42-3) Related Product Information
Anagrelide Impurity 4 6,7-dichloro-3-hydroxy-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one Ethyl-2-(6-aMino-2,3-dichlorobenzylaMino)acetate Hydrochloride Dihydromyrcenol Sulfaquinoxaline Imidazolidine ANAGRELIDE HCL,ANAGRELIDE HYDROCHLORIDE Quinazoline ANAGRELIDE HCL MONOHYDRATE ANAGRELIDE IMPURITY 1 ANAGRELIDE IMPURITY 2 5-ACETOXY ANAGRELIDE ANAGRELIDE IMPURITY 5 Anagrelide Imidazoline inhibitor ANAGRELIDE-13C2,15N1